The frequent gene mutations in ATC include TP53 (54.4%), RAS (43%), BRAF (13.8%), PI3K-AKT pathway mutation (17%).[4,8] The most common gene mutations in cases of ATC coexisting with thyroid papillary carcinoma are BRAFV600E (90%) and TERT promoter mutations (95%).[9] In the current case, both ATC and PTC components had BRAFV600E mutation, further indicating that the ATC component was the dedifferentiated component of the papillary carcinoma. Here, TP53 is linked to differentiated thyroid carcinoma.